Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...
Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to enhance shareholder value.
Sanofi (SNY) Q4 2024 Earnings Call Transcript
Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the usual forward-looking statements.
MasterCard: Q4 Earnings Snapshot
The average estimate of 14 analysts surveyed by Zacks Investment Research was for earnings of $3.68 per share. The processor of debit and credit card payments posted revenue of $7.49 billion in the period,
Sanofi: Q4 Earnings Snapshot
Sanofi (SNY) on Thursday reported fourth-quarter earnings of $728.6 million. The company said it had net income of 29 cents per share. Earnings, adjusted for non-recurring costs and to account for discontinued operations,
FirstCash: Q4 Earnings Snapshot
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $2.02 per share. The pawn store posted revenue of $883.8 million in the period. For the year, the company reported profit of $258.
Corning: Q4 Earnings Snapshot
The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 56 cents per share. Advertisement Article continues below this ad The specialty glass maker posted revenue of $3.
Sanofi CEO Paul Hudson on Q4 results: We've set ourselves up very well for 2025
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, ...
Sanofi plans share buybacks, signals more deals post Opella sale
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...
Pharm Exec17h
Roundup: Top Pharma Companies Report Q4 Earnings, Highlighting Revenue Trends and Market Shifts
Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...
Sanofi reports Q4 IRFS EPS EUR 0.54
Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...
Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...
Time To Be Bullish On Sanofi Ahead Of Its Earnings
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: ...
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of 10.3% at CER1 and business EPS2 ...